| Year |
Citation |
Score |
| 2022 |
Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide. Pediatric Blood & Cancer. e30020. PMID 36151992 DOI: 10.1002/pbc.30020 |
0.466 |
|
| 2022 |
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, ... ... Bindra RS, et al. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Oncotarget. 13: 1054-1067. PMID 36128328 DOI: 10.18632/oncotarget.28273 |
0.302 |
|
| 2022 |
Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Mechanism-based design of agents that selectively target drug-resistant glioma. Science (New York, N.Y.). 377: 502-511. PMID 35901163 DOI: 10.1126/science.abn7570 |
0.315 |
|
| 2021 |
Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in Mutant Mesenchymal Sarcomas. Jco Precision Oncology. 5: 466-472. PMID 34994649 DOI: 10.1200/PO.20.00247 |
0.521 |
|
| 2021 |
Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, ... ... Bindra RS, et al. Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'. Nar Cancer. 3: zcab047. PMID 34888524 DOI: 10.1093/narcan/zcab047 |
0.47 |
|
| 2021 |
Gueble SE, Bindra RS. Oncometabolites as Regulators of DNA Damage Response and Repair. Seminars in Radiation Oncology. 32: 82-94. PMID 34861999 DOI: 10.1016/j.semradonc.2021.09.004 |
0.348 |
|
| 2021 |
Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, ... ... Bindra RS, et al. Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity. Nar Cancer. 3: zcab021. PMID 34316708 DOI: 10.1093/narcan/zcab021 |
0.536 |
|
| 2021 |
Garbarino J, Eckroate J, Sundaram RK, Jensen RB, Bindra RS. Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. Translational Oncology. 14: 101147. PMID 34118569 DOI: 10.1016/j.tranon.2021.101147 |
0.333 |
|
| 2021 |
Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS. Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. Nar Cancer. 3: zcab018. PMID 34027408 DOI: 10.1093/narcan/zcab018 |
0.35 |
|
| 2021 |
Paradkar S, Herrington J, Hendricson A, Hewawasam P, Plummer M, Hoyer D, Sundaram RK, Surovtseva YV, Bindra RS. Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore. Oncotarget. 12: 891-906. PMID 33953843 DOI: 10.18632/oncotarget.27933 |
0.329 |
|
| 2020 |
Chen Y, Jiang T, Zhang H, Gou X, Han C, Wang J, Chen AT, Ma J, Liu J, Chen Z, Jing X, Lei H, Wang Z, Bao Y, Baqri M, ... ... Bindra RS, et al. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nature Cell Biology. 22: 1276-1285. PMID 33005030 DOI: 10.1038/s41556-020-00586-6 |
0.338 |
|
| 2020 |
Hong CS, Vasquez JC, Kundishora AJ, Elsamadicy AA, Beckta JM, Sule A, Marks AM, Leelatian N, Huttner A, Bindra RS, DiLuna ML, Kahle KT, Erson-Omay EZ. Persistent mutation despite multimodal therapy in recurrent pediatric glioblastoma. Npj Genomic Medicine. 5: 23. PMID 32528726 DOI: 10.1038/S41525-020-0130-7 |
0.371 |
|
| 2020 |
Sulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, Noronha K, Bao X, Li J, Shuch BM, King MC, Bindra RS, Glazer PM. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature. PMID 32494005 DOI: 10.1038/S41586-020-2363-0 |
0.626 |
|
| 2020 |
Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, et al. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro-Oncology. PMID 32328653 DOI: 10.1093/Neuonc/Noaa106 |
0.341 |
|
| 2020 |
Gayle S, Aiello R, Bechtold J, Bourassa P, Csengery J, Deshpande K, Jones K, Lopresti-Morrow L, Maguire R, Marshall D, Moore H, Paradis T, Tylaska L, Zhang Q, Volkmann R, ... Bindra RS, et al. Abstract 6242: Development of alphalex™-toxin low pH targeting conjugates for the treatment of solid tumors Cancer Research. 80: 6242-6242. DOI: 10.1158/1538-7445.Am2020-6242 |
0.548 |
|
| 2020 |
Sule AD, Sundaram R, Bindra R. Abstract 1059: Targeting IDH1/2 mutant cancers with unique combinations of DNA repair inhibitors Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1059 |
0.416 |
|
| 2019 |
Beckta JM, Bindra RS, Chalmers AJ. Targeting DNA repair in gliomas. Current Opinion in Neurology. PMID 31592790 DOI: 10.1097/Wco.0000000000000760 |
0.346 |
|
| 2019 |
Fons NR, Sundaram RK, Breuer GA, Peng S, McLean RL, Kalathil AN, Schmidt MS, Carvalho DM, Mackay A, Jones C, Carcaboso ÁM, Nazarian J, Berens ME, Brenner C, Bindra RS. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nature Communications. 10: 3790. PMID 31439867 DOI: 10.1038/S41467-019-11732-6 |
0.419 |
|
| 2019 |
Gallitto M, Lazarev S, Wasserman I, Stafford JM, Wolden SL, Terezakis SA, Bindra RS, Bakst RL. Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. Advances in Radiation Oncology. 4: 520-531. PMID 31360809 DOI: 10.1016/J.Adro.2019.03.009 |
0.309 |
|
| 2019 |
Jackson CB, Noorbakhsh SI, Sundaram RK, Kalathil AN, Ganesa S, Jia L, Breslin H, Burgenske DM, Gilad O, Sarkaria JN, Bindra RS. Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors. Cancer Research. PMID 31273061 DOI: 10.1158/0008-5472.Can-18-3394 |
0.466 |
|
| 2019 |
Bindra R, Sundaram RK, Aiello RJ, Marshall D, Bourassa P, Csengery J, Zhang Q, Robinson B, lopresti-Morrow L, Bechtold J, Tylaska L, Paradis T, Paralkar V, Hellsund P, Glazer P. Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform. Journal of Clinical Oncology. 37: e14664-e14664. DOI: 10.1200/Jco.2019.37.15_Suppl.E14664 |
0.59 |
|
| 2019 |
Gbyli R, Song Y, Liu W, Gao Y, Chandhok NS, Fu X, Wang X, Patel A, Sundaram R, Tebaldi T, Biancon G, Ardasheva A, Qin A, Sadykov M, Mamillapalli P, ... ... Bindra R, et al. PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors Blood. 134: 4222-4222. DOI: 10.1182/Blood-2019-130814 |
0.394 |
|
| 2019 |
Chandhok NS, Wei W, Bindra R, Halene S, Shyr Y, Li J, Berens M, Karlovich C, Ivy SP, Prebet T. The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood. 134: 3909-3909. DOI: 10.1182/Blood-2019-129168 |
0.409 |
|
| 2019 |
Sulkowski PS, Oeck S, Li J, Shuch B, King MC, Bindra RS, Glazer PM. Abstract SY21-02: Oncometabolites suppress homologous recombination DNA repair by inhibition of chromatin remodeling at the DNA double-strand break Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Sy21-02 |
0.635 |
|
| 2019 |
Paralkar V, Aiello RJ, Marshall D, Csengery J, Bourassa P, Zhang Q, Robinson BS, Lopresti-Morrow L, Bechtold J, Tylaska L, Paradis T, Slaybaugh G, Visca H, Moshnikova A, Weerakkody D, ... ... Bindra R, et al. Abstract 2981: Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor Cancer Research. 79: 2981-2981. DOI: 10.1158/1538-7445.Am2019-2981 |
0.581 |
|
| 2019 |
Sule A, Bindra R. RDNA-06. TARGETING IDH1/2-MUTANT GLIOMAS WITH UNIQUE COMBINATIONS OF DNA REPAIR INHIBITORS Neuro-Oncology. 21: vi208-vi208. DOI: 10.1093/Neuonc/Noz175.866 |
0.457 |
|
| 2019 |
Jackson C, Kalathil A, Bindra R. EXTH-55. TEMOZOLOMIDE-RESISTANT GLIOMA CELLS ARE SENSITIVE TO CHLOROETHYLATING NITROSOUREA COMPOUNDS IN COMBINATION WITH ATR INHIBITORS Neuro-Oncology. 21: vi94-vi94. DOI: 10.1093/Neuonc/Noz175.386 |
0.338 |
|
| 2019 |
Jackson C, Noorbakhsh S, Kalathil A, Sundaram R, Bindra R. MGMT-Deficiency Is a Biomarker to Guide Treatment of Solid Tumors with Temozolomide and ATR Inhibitors International Journal of Radiation Oncology*Biology*Physics. 105: E638-E639. DOI: 10.1016/J.Ijrobp.2019.06.1097 |
0.329 |
|
| 2018 |
Neel BG, Xu Y, Taylor P, Andrade J, Ueberheide B, Shuch B, Glazer PM, Bindra RS, Moran MF, Linehan WM. Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research. PMID 30297534 DOI: 10.1158/0008-5472.Can-18-0901 |
0.533 |
|
| 2018 |
Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nature Genetics. PMID 30013182 DOI: 10.1038/S41588-018-0170-4 |
0.623 |
|
| 2018 |
Marks AM, Bindra RS, DiLuna ML, Huttner A, Jairam V, Kahle KT, Kieran MW. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatric Blood & Cancer. PMID 29380516 DOI: 10.1002/Pbc.26969 |
0.34 |
|
| 2018 |
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet. Oncology. 19: 23-24. PMID 29304353 DOI: 10.1016/S1470-2045(17)30916-6 |
0.319 |
|
| 2018 |
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Introduction to the Yale Precision Medicine Tumor Board. The Lancet. Oncology. 19: 19-20. PMID 29304351 DOI: 10.1016/S1470-2045(17)30919-1 |
0.305 |
|
| 2018 |
Lester-Coll NH, Supko JG, Kluytenaar J, Pavlik KF, Yu JB, Moliterno J, Piepmeier J, Becker K, Baehring JM, Huttner A, Vortmeyer A, Contessa JN, Ramani R, Lampert R, Yao X, ... Bindra R, et al. Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial. Journal of Clinical Oncology. 36: e14046-e14046. DOI: 10.1200/Jco.2018.36.15_Suppl.E14046 |
0.359 |
|
| 2018 |
Eder JP, Shapiro GI, Cleary JM, Keedy VL, Bindra R, Shuch B, Sklar J, Do K, Juergensmeier J. Abstract CT159: Olaparib combinations (OLAPCO)for homology-directed DNA repairdefects (HDR) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct159 |
0.415 |
|
| 2018 |
Jackson C, Noorbakhsh S, Sundaram R, Kalathil A, Bindra R. RDNA-05. SYNTHETIC SENSITIZATION OF MGMT-DEFICIENT TUMOR CELLS TO TEMOZOLOMIDE USING ATR INHIBITORS Neuro-Oncology. 20: vi222-vi222. DOI: 10.1093/Neuonc/Noy148.921 |
0.361 |
|
| 2018 |
Yu D, Daddacha W, Koyen A, Bastien A, Head P, Dhere V, Nabeta G, Connolly E, Werner E, Madden M, Daly M, Minten E, Whelan D, Zhang H, Anand R, ... ... Bindra R, et al. OC-0377: Targeting a Novel Function for SAMHD1 in DNA Repair for Radiation Therapy and PARP Inhibition Radiotherapy and Oncology. 127: S192-S193. DOI: 10.1016/S0167-8140(18)30687-X |
0.381 |
|
| 2017 |
Ray S, Breuer G, DeVeaux M, Zelterman D, Bindra R, Sweasy JB. DNA polymerase beta participates in DNA End-joining. Nucleic Acids Research. PMID 29161447 DOI: 10.1093/Nar/Gkx1147 |
0.38 |
|
| 2017 |
Daddacha W, Koyen AE, Bastien AJ, Head PE, Dhere VR, Nabeta GN, Connolly EC, Werner E, Madden MZ, Daly MB, Minten EV, Whelan DR, Schlafstein AJ, Zhang H, Anand R, ... ... Bindra RS, et al. SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. Cell Reports. 20: 1921-1935. PMID 28834754 DOI: 10.1016/J.Celrep.2017.08.008 |
0.408 |
|
| 2017 |
Bindra RS, Chalmers AJ, Evans S, Dewhirst M. GBM radiosensitizers: dead in the water…or just the beginning? Journal of Neuro-Oncology. PMID 28762004 DOI: 10.1007/S11060-017-2427-7 |
0.385 |
|
| 2017 |
Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, et al. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. The Journal of Pathology. PMID 28299801 DOI: 10.1002/Path.4890 |
0.424 |
|
| 2017 |
Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, ... ... Bindra RS, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Science Translational Medicine. 9. PMID 28148839 DOI: 10.1126/Scitranslmed.Aal2463 |
0.618 |
|
| 2017 |
Bindra R, Sulkowski PL, Corso CD, Glazer P, Shuch BM. Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors. Journal of Clinical Oncology. 35: 11586-11586. DOI: 10.1200/Jco.2017.35.15_Suppl.11586 |
0.618 |
|
| 2017 |
Hollick JJ, Abriola L, Bono F, Hegan D, Klingbeil P, Liu Y, Sundaram R, Surovtseva YV, Whittaker M, Bindra RS, Glazer PM. Abstract B25: “TargetDBR”—A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate DNA repair targeted drug discovery Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B25 |
0.629 |
|
| 2017 |
Sulkowski P, Corso C, Robinson N, Scanlon S, Purshouse K, Bai H, Liu Y, Sundaram R, Hegan D, Fons N, Breuer G, Song Y, Mishra K, Feyter HD, Graaf Rd, ... ... Bindra RS, et al. Abstract LB-290: Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitors Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-290 |
0.634 |
|
| 2017 |
Ray S, DeVeaux M, Breuer G, Bindra R, Zelterman D, Sweasy J. Abstract 2492: DNA polymerase beta participates in DNA end-joining Cancer Research. 77: 2492-2492. DOI: 10.1158/1538-7445.Am2017-2492 |
0.388 |
|
| 2017 |
Corso C, Bindra R, Glazer P, Sulkowski P, Robinson N, Scanlon S, Purshouse K, Bai H, Liu Y, Sundaram R, Hegan D, Fons N, Breuer G, Song Y, Mishra-Gorur K, et al. Production of 2-Hydroxyglutarate by IDH Mutant Malignancies Induces a BRCAness State That Can be Exploited By PARP Inhibitors and Radiation International Journal of Radiation Oncology*Biology*Physics. 99: E68. DOI: 10.1016/J.Ijrobp.2017.06.754 |
0.525 |
|
| 2016 |
Gao S, Surovtseva Y, Bindra RS. RNF8 Regulates Nonhomologous End Joining and DNA-PK Recruitment to DNA Double-Strand Break Sites. International Journal of Radiation Oncology, Biology, Physics. 96: S55. PMID 27675958 DOI: 10.1016/J.Ijrobp.2016.06.143 |
0.365 |
|
| 2016 |
Janssen A, Breuer GA, Brinkman EK, van der Meulen AI, Borden SV, van Steensel B, Bindra RS, LaRocque JR, Karpen GH. A single double-strand break system reveals repair dynamics and mechanisms in heterochromatin and euchromatin. Genes & Development. 30: 1645-57. PMID 27474442 DOI: 10.1101/Gad.283028.116 |
0.372 |
|
| 2016 |
Surovtseva YV, Jairam V, Salem AF, Sundaram RK, Bindra RS, Herzon SB. Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole cell double immunofluorescence assay. Journal of the American Chemical Society. PMID 26927829 DOI: 10.1021/Jacs.6B00162 |
0.402 |
|
| 2016 |
Bindra RS, Wolden SL. Advances in Radiation Therapy in Pediatric Neuro-oncology. Journal of Child Neurology. 31: 506-16. PMID 26271789 DOI: 10.1177/0883073815597758 |
0.333 |
|
| 2016 |
Robinson ND, Purshouse KR, Fons NR, Breuer GA, Pusch S, Deimling Av, Sundaram RK, Bindra RS. Abstract 4277: Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas Cancer Research. 76: 4277-4277. DOI: 10.1158/1538-7445.Am2016-4277 |
0.435 |
|
| 2016 |
Fons NR, Surovtseva Y, Breuer GA, Sundaram RK, Bindra RS. Abstract 2466: Development of a novel gene targeting and clone screening platform to engineer common pediatric glioma mutations into model cell lines Cancer Research. 76: 2466-2466. DOI: 10.1158/1538-7445.Am2016-2466 |
0.366 |
|
| 2016 |
Surovtseva Y, Jairam V, Sundaram R, Bindra R, Herzon S. Abstract 2174: A high-throughput, high-content assay for the discovery of new inhibitors of DNA double-strand break repair Cancer Research. 76: 2174-2174. DOI: 10.1158/1538-7445.Am2016-2174 |
0.413 |
|
| 2015 |
Soong CP, Breuer GA, Hannon RA, Kim SD, Salem AF, Wang G, Yu R, Carriero NJ, Bjornson R, Sundaram RK, Bindra RS. Development of a novel method to create double-strand break repair fingerprints using next-generation sequencing. Dna Repair. 26: 44-53. PMID 25547252 DOI: 10.1016/J.Ijrobp.2013.06.057 |
0.409 |
|
| 2015 |
Goglia AG, Delsite R, Luz AN, Shahbazian D, Salem AF, Sundaram RK, Chiaravalli J, Hendrikx PJ, Wilshire JA, Jasin M, Kluger HM, Glickman JF, Powell SN, Bindra RS. Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors. Molecular Cancer Therapeutics. 14: 326-42. PMID 25512618 DOI: 10.1158/1535-7163.Mct-14-0765 |
0.462 |
|
| 2015 |
Lester-Coll NH, Kluytenaar J, Pavlik KF, Yu JB, Contessa JN, Moliterno J, Piepmeier JM, Becker KP, Baehring JM, Huttner AJ, Vortmeyer AO, Ramani R, Lampert RJ, Yao X, Bindra RS. ATNT-15MIBEFRADIL DIHYDROCHORIDE WITH HYPOFRACTIONATED RADIATION FOR RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS OF A PHASE I DOSE EXPANSION TRIAL Neuro-Oncology. 17: v13.3-v13. DOI: 10.1093/Neuonc/Nov205.15 |
0.311 |
|
| 2015 |
Fons N, Sundaram R, Bindra R. PM-11 * DEVELOPMENT OF A NOVEL GENE TARGETING AND CLONE SCREENING PLATFORM TO ENGINEER COMMON PEDIATRIC GLIOMA MUTATIONS INTO MODEL CELL LINES Neuro-Oncology. 17: iii33-iii33. DOI: 10.1093/Neuonc/Nov061.133 |
0.366 |
|
| 2015 |
Aneja S, Contessa J, Husain Z, Glazer P, Hansen J, Bindra R, Yu J. mRNA Expression of TP53 Attenuates Survival of HPV+ Locally Advanced Head and Neck Cancer International Journal of Radiation Oncology*Biology*Physics. 93: E350-E351. DOI: 10.1016/J.Ijrobp.2015.07.1440 |
0.495 |
|
| 2015 |
Jairam V, Sundaram R, Breuer G, Surovtseva Y, Bindra R. Identification and Characterization of Novel DNA Repair Inhibitors as Potential Tumor Cell Radiosensitizers International Journal of Radiation Oncology*Biology*Physics. 93: S48. DOI: 10.1016/J.Ijrobp.2015.07.116 |
0.447 |
|
| 2014 |
Salem A, Surovtseva Y, Sundaram R, Bindra R. High-Throughput RNAi Screening Platform Identifies Novel Regulators of DNA Double-Strand Break Repair Pathways International Journal of Radiation Oncology*Biology*Physics. 90: S34-S35. DOI: 10.1016/J.Ijrobp.2014.05.146 |
0.382 |
|
| 2013 |
Shahbazian D, Bindra RS, Kluger HM, Glazer PM. Radiation sensitivity and sensitization in melanoma. Pigment Cell & Melanoma Research. 26: 928-30. PMID 23870422 DOI: 10.1111/Pcmr.12147 |
0.525 |
|
| 2013 |
Bindra RS, Goglia AG, Jasin M, Powell SN. Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Research. 41: e115. PMID 23585275 DOI: 10.1093/Nar/Gkt255 |
0.387 |
|
| 2013 |
Salem A, Sundaram R, Surovtseva Y, Bindra R. High-Content, High-Throughput Screening for Novel Double-Strand Break Repair Inhibitors International Journal of Radiation Oncology*Biology*Physics. 87: S654. DOI: 10.1016/J.Ijrobp.2013.06.1732 |
0.314 |
|
| 2011 |
Schleifman EB, Bindra R, Leif J, del Campo J, Rogers FA, Uchil P, Kutsch O, Shultz LD, Kumar P, Greiner DL, Glazer PM. Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chemistry & Biology. 18: 1189-98. PMID 21944757 DOI: 10.1016/J.Chembiol.2011.07.010 |
0.722 |
|
| 2011 |
Powell S, Mutter R, Delsite R, Bindra R, King T, Giri D, Park J. PD10-02: Sporadic Breast Cancers Show Defects in the BRCA1-BRCA2 Pathway of Homologous Recombination in All Biomarker-Defined Sub-Types of Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd10-02 |
0.411 |
|
| 2010 |
Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings of the National Academy of Sciences of the United States of America. 107: 2201-6. PMID 20133863 DOI: 10.1073/Pnas.0904783107 |
0.621 |
|
| 2010 |
Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Abstract 1969: Inhibition of poly(ADP-ribose) polymerase downregulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 Cancer Research. 70: 1969-1969. DOI: 10.1158/1538-7445.Am10-1969 |
0.611 |
|
| 2010 |
Bindra R, Jasin M, Powell S. Development of a Novel Double-strand Break Repair Assay for High-throughput Small Molecule Screening in Glioma Cell Lines International Journal of Radiation Oncology*Biology*Physics. 78: S88. DOI: 10.1016/J.Ijrobp.2010.07.235 |
0.312 |
|
| 2009 |
Glazer PM, Bindra RS. Introduction: the evolving picture of the hypoxic tumour microenvironment. Current Molecular Medicine. 9: 399-400. PMID 19519396 DOI: 10.2174/156652409788167069 |
0.486 |
|
| 2009 |
Powell SN, Bindra RS. Targeting the DNA damage response for cancer therapy. Dna Repair. 8: 1153-65. PMID 19501553 DOI: 10.1016/J.Dnarep.2009.04.011 |
0.452 |
|
| 2008 |
Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Research. 68: 605-14. PMID 18199558 DOI: 10.1158/0008-5472.Can-07-5472 |
0.612 |
|
| 2007 |
Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells Cancer and Metastasis Reviews. 26: 249-260. PMID 17415527 DOI: 10.1007/S10555-007-9061-3 |
0.646 |
|
| 2007 |
Bindra RS, Glazer PM. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Letters. 252: 93-103. PMID 17275176 DOI: 10.1016/J.Canlet.2006.12.011 |
0.619 |
|
| 2007 |
Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. Journal of Molecular Medicine (Berlin, Germany). 85: 139-48. PMID 17180667 DOI: 10.1007/S00109-006-0133-6 |
0.586 |
|
| 2007 |
Bindra RS, Glazer PM. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene. 26: 2048-57. PMID 17001309 DOI: 10.1038/Sj.Onc.1210001 |
0.615 |
|
| 2006 |
Bindra RS, Glazer PM. Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites. Cancer Biology & Therapy. 5: 1400-7. PMID 17106239 DOI: 10.4161/Cbt.5.10.3454 |
0.58 |
|
| 2006 |
Gibson SL, Bindra RS, Glazer PM. CHK2-dependent phosphorylation of BRCA1 in hypoxia. Radiation Research. 166: 646-51. PMID 17007555 DOI: 10.1667/Rr0660.1 |
0.782 |
|
| 2006 |
Bindra R, Gibson S, Crosby M, Glazer P. 86 International Journal of Radiation Oncology*Biology*Physics. 66: S50. DOI: 10.1016/J.Ijrobp.2006.07.116 |
0.738 |
|
| 2005 |
Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Annals of the New York Academy of Sciences. 1059: 184-95. PMID 16382054 DOI: 10.1196/Annals.1339.049 |
0.64 |
|
| 2005 |
Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Research. 65: 11597-604. PMID 16357170 DOI: 10.1158/0008-5472.Can-05-2119 |
0.78 |
|
| 2005 |
Gibson SL, Bindra RS, Glazer PM. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Research. 65: 10734-41. PMID 16322218 DOI: 10.1158/0008-5472.Can-05-1160 |
0.787 |
|
| 2005 |
Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 76: 168-76. PMID 16026872 DOI: 10.1016/J.Radonc.2005.06.025 |
0.582 |
|
| 2005 |
Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutation Research. 569: 75-85. PMID 15603753 DOI: 10.1016/J.Mrfmmm.2004.03.013 |
0.605 |
|
| 2005 |
Bristow R, Meng A, Jalali F, Hedley D, Nichol T, Sweet J, Milosevic M, Bindra R, Glazer P. 67 Expression of DNA-dsb repair proteins is altered under hypoxia in prostate cancer cells Radiotherapy and Oncology. 76: S20-S21. DOI: 10.1016/S0167-8140(05)80228-2 |
0.579 |
|
| 2005 |
Glazer P, Bindra R. Dysregulation of BRCAL in Hypoxia International Journal of Radiation Oncology*Biology*Physics. 63: S145. DOI: 10.1016/J.Ijrobp.2005.07.247 |
0.503 |
|
| 2004 |
Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Molecular and Cellular Biology. 24: 8504-18. PMID 15367671 DOI: 10.1128/Mcb.24.19.8504-8518.2004 |
0.649 |
|
| 2003 |
Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, Giordano F, Johnson RS, Rockwell S, Glazer PM. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Molecular and Cellular Biology. 23: 3265-73. PMID 12697826 DOI: 10.1128/Mcb.23.9.3265-3273.2003 |
0.749 |
|
| Show low-probability matches. |